All In Biotech

Drug Trial Radar · NCT07943377

Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

A Phase 1 Trial in Healthy Participants to Evaluate Single and Multiple Oral Dose Safety, Tolerability, and Pharmacokinetics of Supratherapeutic Doses of ALG-000184 (Parts A and B) and the Absorption, Metabolism, Excretion, and Absolute Bioavailability of ALG-001075 Following a Single Oral Dose of [14C]ALG-000184 and a Single Intravenous Dose of [13C7,15N1]ALG-001075 (Part C)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Aug 6, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Aligos TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1 trial of ALG-000184 in healthy participants to assess the safety and tolerability of single and multiple (if applicable) oral doses of ALG-000184 (Part A and B) and ALG-001075 Following a Single Oral Dose of \[14C\]ALG-000184 and a Single Intravenous Dose of \[13C7,15N1\]ALG-001075 (Part C)

Conditions

  • Healthy Participants

Interventions

  • ALG-000184Drug

    Single or multiple doses of ALG-000184

  • PlaceboDrug

    Single or multiple doses of Placebo

  • [14C]ALG-000184Radiation

    Single oral dose of \[14C\]ALG-000184

  • [13C7,15N1]ALG-001075Radiation

    Single micodose of \[13C7,15N1\]ALG-001075 with combination of \[14C\]ALG-000184

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  2. PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  3. PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  4. PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  5. PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  6. PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  7. PK Parameters (Part A and B)Time frame: From enrollment to end of treatment at 10 days
  8. Total radioactivity recovery (fet1-t2) in urine and feces (Part C)Time frame: From enrollment to end of treatment at 10 days
  9. Metabolic profiles of ALG-000184 (Part C)Time frame: From enrollment to end of treatment at 10 days
  10. Identification of ALG-000184 (Part C)Time frame: From enrollment to end of treatment at 10 days
  11. Bioavailability of ALG-001075 (Part C)Time frame: From enrollment to end of treatment at 10 days
  12. PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
  13. PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
  14. PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
  15. PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days
  16. PK parameters (Part C)Time frame: From enrollment to end of treatment at 10 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aligos Investigational Site

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.